FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089749516> ?p ?o ?g. }

• W2089749516 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLMultiple myeloma (MM), a clonal malignancy of plasma cells, is the second most common adult hematological malignancy with approximately 15,000 new cases diagnosed annually. Despite recent advances in its clinical management, morbidity and mortality associated with MM remain high and there is a need for continuing development of novel anti-myeloma agents. Nexrutine, a non-toxic herbal extract from the bark of Chinese tree Phellodendron amurense, has been shown to exert significant anti-tumor effects in animal models of prostate cancer and is currently being evaluated in phase I/II clinical trials in patients with prostate cancer. In this study, we investigated the potential anti-tumor effect of nexrutine in MM. Exposure to nexrutine (3-100µg/ml) reduced viability of murine 5TGM1 and human RPMI 8226 MM cells in a dose- and time-dependent manner, independent of cell cycle disruption. Loss of cell viability was due primarily to apoptosis as indicated by >2-fold increase in annexin V+, 7AAD- cells and increased DNA fragmentation detectable by 24 hours. Previous studies showed that down-regulation of short-lived anti-apoptotic protein myeloid cell leukemia-1 (Mcl-1), in part by caspase-dependent cleavage of the full-length protein (Mcl-1L) to generate smaller (pro-apoptotic) Mcl-1 fragments, plays a major role in execution of apoptosis in MM cells. Nexrutine-induced apoptosis in MM cells was associated with reduced levels of Mcl-1L, caspase activation as indicated by a large increase in the active 17kDa cleavage product of procaspase 3 and an increase in pro-apoptotic Mcl-1 cleavage product. Nexrutine also inhibited the mammalian target of rapamycin (mTOR) and this was accompanied by accumulation of LC3-II, a marker of autophagosomes, in autophagy-competent MM cells. However, treatment of MM with cells with either pepstatin A and E64D that target lysosomal proteases involved in autophagy or with chloroquine, a lysosomotrophic autophagy inhibitor also resulted in cytotoxicity and these autophagy inhibitors did not rescue nexrutine-induced loss of viability in MM cells suggesting that autophagy plays a role constitutively in MM cell survival. Finally, we evaluated potential in vivo anti-tumor efficacy of nexrutine in the well-characterized preclinical model of MM in which 5TGM1 cells are inoculated intravenously in syngeneic naive female C57BL/KaLwRij mice. Administration of nexrutine (400µg/mouse p.o. by gavage 6 days/week for 5 weeks) to tumor-bearing mice reduced serum levels of the monoclonal IgG2bκ paraprotein, a surrogate for tumor progression and overall tumor burden. Collectively, our results indicate an anti-myeloma effect of nexrutine and support further extensive preclinical testing and early phase clinical trial of this non-toxic herbal extract in MM. Our data also indicate that a combination of nexrutine and one or more autophagy inhibitors would result in enhanced anti-tumor effect in MM.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4216. doi:10.1158/1538-7445.AM2011-4216" @default.
• W2089749516 created "2016-06-24" @default.
• W2089749516 creator A5000043199 @default.
• W2089749516 creator A5016442413 @default.
• W2089749516 creator A5018665892 @default.
• W2089749516 creator A5087746790 @default.
• W2089749516 date "2011-04-15" @default.
• W2089749516 modified "2023-09-26" @default.
• W2089749516 title "Abstract 4216: Antitumor effect of Nexrutine, a phellodendron amurense bark extract, in multiple myeloma" @default.
• W2089749516 doi "https://doi.org/10.1158/1538-7445.am2011-4216" @default.
• W2089749516 hasPublicationYear "2011" @default.
• W2089749516 type Work @default.
• W2089749516 sameAs 2089749516 @default.
• W2089749516 citedByCount "1" @default.
• W2089749516 countsByYear W20897495162015 @default.
• W2089749516 crossrefType "proceedings-article" @default.
• W2089749516 hasAuthorship W2089749516A5000043199 @default.
• W2089749516 hasAuthorship W2089749516A5016442413 @default.
• W2089749516 hasAuthorship W2089749516A5018665892 @default.
• W2089749516 hasAuthorship W2089749516A5087746790 @default.
• W2089749516 hasConcept C105696609 @default.
• W2089749516 hasConcept C121608353 @default.
• W2089749516 hasConcept C126322002 @default.
• W2089749516 hasConcept C190283241 @default.
• W2089749516 hasConcept C203014093 @default.
• W2089749516 hasConcept C2776364478 @default.
• W2089749516 hasConcept C2779399171 @default.
• W2089749516 hasConcept C29537977 @default.
• W2089749516 hasConcept C31573885 @default.
• W2089749516 hasConcept C43759708 @default.
• W2089749516 hasConcept C502942594 @default.
• W2089749516 hasConcept C53227056 @default.
• W2089749516 hasConcept C553184892 @default.
• W2089749516 hasConcept C55493867 @default.
• W2089749516 hasConcept C71924100 @default.
• W2089749516 hasConcept C86803240 @default.
• W2089749516 hasConcept C88634738 @default.
• W2089749516 hasConcept C96232424 @default.
• W2089749516 hasConcept C98274493 @default.
• W2089749516 hasConceptScore W2089749516C105696609 @default.
• W2089749516 hasConceptScore W2089749516C121608353 @default.
• W2089749516 hasConceptScore W2089749516C126322002 @default.
• W2089749516 hasConceptScore W2089749516C190283241 @default.
• W2089749516 hasConceptScore W2089749516C203014093 @default.
• W2089749516 hasConceptScore W2089749516C2776364478 @default.
• W2089749516 hasConceptScore W2089749516C2779399171 @default.
• W2089749516 hasConceptScore W2089749516C29537977 @default.
• W2089749516 hasConceptScore W2089749516C31573885 @default.
• W2089749516 hasConceptScore W2089749516C43759708 @default.
• W2089749516 hasConceptScore W2089749516C502942594 @default.
• W2089749516 hasConceptScore W2089749516C53227056 @default.
• W2089749516 hasConceptScore W2089749516C553184892 @default.
• W2089749516 hasConceptScore W2089749516C55493867 @default.
• W2089749516 hasConceptScore W2089749516C71924100 @default.
• W2089749516 hasConceptScore W2089749516C86803240 @default.
• W2089749516 hasConceptScore W2089749516C88634738 @default.
• W2089749516 hasConceptScore W2089749516C96232424 @default.
• W2089749516 hasConceptScore W2089749516C98274493 @default.
• W2089749516 hasLocation W20897495161 @default.
• W2089749516 hasOpenAccess W2089749516 @default.
• W2089749516 hasPrimaryLocation W20897495161 @default.
• W2089749516 hasRelatedWork W1581454711 @default.
• W2089749516 hasRelatedWork W1996558052 @default.
• W2089749516 hasRelatedWork W2013069287 @default.
• W2089749516 hasRelatedWork W2313815949 @default.
• W2089749516 hasRelatedWork W2411795098 @default.
• W2089749516 hasRelatedWork W2529420833 @default.
• W2089749516 hasRelatedWork W2538514347 @default.
• W2089749516 hasRelatedWork W2555646772 @default.
• W2089749516 hasRelatedWork W2573779331 @default.
• W2089749516 hasRelatedWork W2580363492 @default.
• W2089749516 hasRelatedWork W2580443814 @default.
• W2089749516 hasRelatedWork W2581397389 @default.
• W2089749516 hasRelatedWork W2583453014 @default.
• W2089749516 hasRelatedWork W2583620316 @default.
• W2089749516 hasRelatedWork W2588951776 @default.
• W2089749516 hasRelatedWork W2590339526 @default.
• W2089749516 hasRelatedWork W2620604297 @default.
• W2089749516 hasRelatedWork W2902184543 @default.
• W2089749516 hasRelatedWork W2979490967 @default.
• W2089749516 hasRelatedWork W2979896473 @default.
• W2089749516 isParatext "false" @default.
• W2089749516 isRetracted "false" @default.
• W2089749516 magId "2089749516" @default.
• W2089749516 workType "article" @default.